Bazinet, M., Pântea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Albrecht, J., Schmid, P., Le Gal, F., Gordien, E., Krawczyk, A., Mijočević, H., Karimzadeh, H., Roggendorf, M., & Vaillant, A. (2017). safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet gastroenterology and hepatology, 2, 877–889. http://access.bl.uk/ark:/81055/vdc_100053781484.0x000001